Cargando…

Regulatory Aspects in Using Surrogate Markers in Clinical Trials

Detalles Bibliográficos
Autor principal:	Chakravarty, Aloka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2005
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123225/ http://dx.doi.org/10.1007/0-387-27080-9_3

Ejemplares similares

Surrogate markers in antiangiogenesis clinical trials
por: Davis, D W, et al.
Publicado: (2003)

Role of Surrogate Markers of Atherosclerosis in Clinical and Subclinical Thyroidism
por: Gunduz, Mehmet, et al.
Publicado: (2012)

Outcomes and potential surrogate markers for future clinical trials of non‐alcoholic steatohepatitis cirrhosis
por: Rivera‐Esteban, Jesús, et al.
Publicado: (2021)

Surrogate Adiposity Markers and Mortality
por: Khan, Irfan, et al.
Publicado: (2023)

Defining vitamin D deficiency, using surrogate markers
por: Garg, M. K., et al.
Publicado: (2013)

Lipid indices as simple and clinically useful surrogate markers for insulin resistance in the U.S. population
por: Lee, Juncheol, et al.
Publicado: (2021)

Insulin Resistance: Quest for Surrogate Markers
por: Mahajan, Rajiv
Publicado: (2017)

Surrogate end points and their role in clinical trial
por: Jaykaran,
Publicado: (2009)

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
por: Kemp, Robert, et al.
Publicado: (2017)

Perspectives on statistical strategies for the regulatory biomarker qualification process
por: Hendrix, Suzanne B, et al.
Publicado: (2021)

Clinical surrogate markers for predicting metabolic syndrome in middle‐aged and elderly Chinese
por: Li, Rui, et al.
Publicado: (2017)

DNA Methylation as Surrogate Marker For Gastric Cancer
por: Oh, Jung-Hwan, et al.
Publicado: (2015)

Erythema as a Visual Surrogate Marker of Glucagonoma
por: Ochi, Nobuaki, et al.
Publicado: (2018)

Tryptophan as a surrogate prognostic marker for diabetic nephropathy
por: Chou, Chien‐An, et al.
Publicado: (2017)

Homa-adiponectin index as useful surrogate marker in the screeening of insulin resistance
por: Vilela, Brunna Sullara, et al.
Publicado: (2015)

Response to the editorial on “Defining vitamin D deficiency, using surrogate markers”
por: Chakraborty, Subhosmito, et al.
Publicado: (2014)

Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases
por: Thompson, George R, et al.
Publicado: (2022)

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria
por: Jeeyapant, Atthanee, et al.
Publicado: (2017)

Identification of Neutrophil Activation Markers as Novel Surrogate Markers of CF Lung Disease
por: Rath, Timo, et al.
Publicado: (2014)

Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Regulatory Aspects of Clinical Trials in Iran: Third Year Report of Clinical Trial Committee in Food and Drug Organization
por: HOSSEINI, Seyed Ali Reza, et al.
Publicado: (2013)

Leukocyte infiltration as a surrogate marker for diagnosis of invasion
por: Liu, Aijun, et al.
Publicado: (2010)

T4. IDENTIFICATION OF NEUROANATOMICAL SURROGATE MARKERS OF CHILDHOOD TRAUMA
por: Haidl, Theresa, et al.
Publicado: (2018)

The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer.
por: Mackillop, W. J., et al.
Publicado: (1986)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Quantitative Proteomic Analysis of Meningiomas for the Identification of Surrogate Protein Markers
por: Sharma, Samridhi, et al.
Publicado: (2014)

Urea and protein carbamylation in ESRD: Surrogate markers or partners in crime?
por: Velasquez, Manuel T, et al.
Publicado: (2015)

Serum malondialdehyde level: Surrogate stress marker in the Sikkimese diabetics
por: Bhutia, Yazum, et al.
Publicado: (2011)

Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers
por: Morel, Alix, et al.
Publicado: (2021)

Effects of Vitamin D Supplementation on Surrogate Markers of Fertility in PCOS Women: A Randomized Controlled Trial
por: Lerchbaum, Elisabeth, et al.
Publicado: (2021)

Glycemic Gap as a Useful Surrogate Marker for Glucose Variability and Progression of Diabetic Retinopathy
por: Hsing, Shi-Chue, et al.
Publicado: (2021)

Issues in biochemical applications to risk assessment: when can lymphocytes be used as surrogate markers?
por: Lucier, G W, et al.
Publicado: (1987)

Late Post-Conditioning with Sevoflurane after Cardiac Surgery - Are Surrogate Markers Associated with Clinical Outcome?
por: Bonvini, John M., et al.
Publicado: (2015)

Evaluation of Potential Clinical Surrogate Markers of a Trauma Induced Alteration of Clotting Factor Activities
por: Burggraf, Manuel, et al.
Publicado: (2016)

Corrected QT interval on the electrocardiogram after liver transplantation: Surrogate marker of poor clinical outcomes?
por: Lee, Seung-Hwa, et al.
Publicado: (2018)

Clinical outcomes: to be a surrogate or not to be ...?
por: Cameron, David
Publicado: (2007)

Triglyceride Glucose-Body Mass Index Is a Simple and Clinically Useful Surrogate Marker for Insulin Resistance in Nondiabetic Individuals
por: Er, Leay-Kiaw, et al.
Publicado: (2016)

Is procalcitonin a new surrogate marker for hypoxic brain damage?
por: Fries, M, et al.
Publicado: (2002)

A surrogate marker for Aβ42 production in the CNS
por: Holtzman, David M
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_0l3jsg7dp6kmh2k1b3g687ee9o